+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis



Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis



Osteoporosis International 27(6): 2117-2126



Gastroesophageal reflux disease (GERD) with proton pump inhibitor (PPI) use is associated with an increased risk of osteoporosis. The risk of hip fracture is not increased in GERD patients with PPI use. The relationship between GERD with PPI treatment and the risk of osteoporosis is unclear. We aimed to determine the risk of developing osteoporosis in patients diagnosed with GERD. Patients diagnosed with GERD and received PPI treatment between 2000 and 2010 were identified from the Longitudinal Health Insurance Database as the study cohort (n = 10,620), which was frequency matched with the comparison cohort (n = 20,738) sampled from the general population according to age, sex, index year, and comorbidities. Both cohorts were followed until the end of 2011. The risk of osteoporosis was evaluated in both groups by using Cox proportional hazards regression models. The GERD patients with PPI treatment had a greater incidence (31.4 vs 20.7 per 1000 person-year; crude hazard ratio [cHR] 1.51; 95 % confidence interval [CI] 1.40-1.63) and a higher risk (adjusted HR [aHR] 1.50; 95 % CI 1.39-1.62) of osteoporosis than that of the comparison cohort. However, the overall incidence of hip fracture was not different between the GERD with PPI use and the control cohorts (aHR 0.79; 95 % CI 0.53-1.18). GERD with PPI use is associated with an increased risk of osteoporosis. The findings of our study do not support an increased risk of hip fracture in GERD patients treated with a PPI.

(PDF emailed within 0-6 h: $19.90)

Accession: 057919543

Download citation: RISBibTeXText

PMID: 26860609

DOI: 10.1007/s00198-016-3510-1


Related references

Increased risk of concurrent asthma among patients with gastroesophageal reflux disease: a nationwide population-based study. European Journal of Gastroenterology and Hepatology 22(10): 1169-1173, 2010

Increased risk of concurrent gastroesophageal reflux disease among patients with Sjögren's syndrome: A nationwide population-based study. European Journal of Internal Medicine 31: 73-78, 2017

Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scandinavian Journal of Gastroenterology 48(9): 1010-1017, 2014

Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis--a nationwide population-based cohort study. International Journal of Clinical Practice 69(3): 350-357, 2016

Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. Journal of Neurogastroenterology and Motility 19(1): 61-69, 2013

Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain. Diseases of the Esophagus 29(4): 367-376, 2017

Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor. Journal of Gastroenterology and Hepatology 23(2): 303-309, 2007

Gastroesophageal reflux disease and risk for bipolar disorder: a nationwide population-based study. Plos One 9(9): E107694, 2015

Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease. Gastroenterology 139(1): 7-13.E3, 2010

Role of Acid and weakly acidic reflux in gastroesophageal reflux disease off proton pump inhibitor therapy. Journal of Neurogastroenterology and Motility 18(3): 291-297, 2012

Risk of psychiatric disorders following gastroesophageal reflux disease: a nationwide population-based cohort study. European Journal of Internal Medicine 26(7): 534-539, 2016

Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology 46(7-8): 789-796, 2012

Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion 86(4): 315-322, 2013

Distal esophageal reflux accompanies nocturnal gastric acid breakthrough in patients with gastroesophageal reflux disease on proton pump inhibitor bid. Gastroenterology 114(4 PART 2): A56-A57, April 15, 1998

Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology 12(10): 1647-1655, 2015